Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Last trade$163.20
Day change-$3.67 (-2.20%)
Day range$161.75 – $172.00
Volume1,497,972
Market cap$36.09B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$36.09B
Price / earnings
—
Price / book
15.03×
Price / sales
182.69×
EV / sales
182.05×
EV / EBITDA
-21.47×
Profitability
Earnings per share
-$8.65
Return on assets
-43.47%
Return on equity
-77.89%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.2×
Current ratio
8.36×
Quick ratio
8.34×
Cash ratio
1.29×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$1.44B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RVMD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$197.56M
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$327K
$0
$0
$0
$0
$0
$0
$0
Gross profit
$197.23M
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$153.29M
$110.21M
$101.25M
$66.68M
$52.76M
$40.58M
$35.01M
$28.21M
Research and development
$417.09M
$394.92M
$343.97M
$294.94M
$262.51M
$224.13M
$205.75M
$188.1M
Total operating expenses
$570.38M
$505.13M
$445.22M
$361.63M
$315.27M
$264.71M
$240.76M
$216.31M
Operating income
-$373.15M
-$505.13M
-$445.22M
-$361.63M
-$315.27M
-$264.71M
-$240.76M
-$216.31M
Interest expense
-$33.8M
-$23.78M
-$12.2M
-$11.94M
-$11.43M
-$867K
$0
$0
Income before taxes
-$409.81M
-$644.37M
-$453.82M
-$364.89M
-$305.21M
-$247.79M
-$213.42M
-$195.32M
Income taxes
-$2.35M
$0
$0
$0
$0
$0
$0
-$753K
Net income
-$407.46M
-$644.37M
-$453.82M
-$364.89M
-$305.21M
-$247.79M
-$213.42M
-$194.57M
Net income attributable to common shareholders
-$407.46M
-$644.37M
-$453.82M
-$364.89M
-$305.21M
-$247.79M
-$213.42M
-$194.57M
EBITDA
-$370.19M
-$502.68M
-$442.88M
-$359.29M
-$312.94M
-$262.69M
-$238.8M
-$214.31M
Basic earnings per share
-$1.90
-$3.06
-$2.29
-$1.88
-$1.61
-$1.31
-$1.13
-$1.12
Diluted earnings per share
-$1.90
-$3.06
-$2.29
-$1.88
-$1.61
-$1.31
-$1.13
-$1.12
Recent news
Company coverage with links to the original publishers.
The European Commission has approved RASONQUE (daraxonrasib) by Revolution Medicines for treating adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The approval, based on positive Phase 3 RASolute 302 trial results, represents a significant advancement for pancreatic cancer treatment in the EU, with the company working to enable patient access through national pricing and reimbursement processes.
The FDA issued a not approvable letter for NovoCure's Optune Mya device for treating lung cancer brain metastases, citing uncertainty around clinical benefit despite no safety concerns. The rejection compounds investor concerns following lackluster Q3 earnings and competition from Revolution Medicines' newly approved Rasonque pill for pancreatic cancer. NovoCure's stock fell 7.34% on the news, and the analyst recommends against investing in the beaten-down equity.
Revolution Medicines (RVMD) has a mean analyst price target of $266.88, suggesting 33.3% upside potential from its current $200.15 price. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions with 9 out of 10 recent estimates moving higher. However, the article cautions that price targets should not be the sole basis for investment decisions, as they often reflect analyst bias and business incentives rather than accurate predictions.
Wall Street analysts project a 53.4% upside for Flotek Industries (FTK) with a mean price target of $39.85. The stock has gained 1.3% over four weeks and currently trades at $25.98. Strong agreement among analysts on upward earnings estimate revisions and a Zacks Rank #1 (Strong Buy) rating support the positive outlook, though the article cautions that price targets alone should not drive investment decisions.
Light & Wonder (LNWO) has gained 2.5% over the past four weeks and Wall Street analysts project a mean upside of 35.3% based on consensus price targets. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that analyst price targets can be misleading and should not be the sole basis for investment decisions, as they often reflect business incentives rather than realistic valuations.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.